Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure: Converging on NF-κB

    Seeking cysteines Targets & Mechanisms Converging on NF-κB In a Science Signaling study published last month, researchers from The Scripps Research Institute investigated how the multiple sclerosis drug Tecfidera …

    Published on 10/6/2016
  • Figure: Targeting cysteines

    Seeking cysteines Targets & Mechanisms Targeting cysteines In a Science Signaling study published last month, researchers at The Scripps Research Institute identified two cysteines in PKCθ - Cys14 and Cys17 (yellow…

    Published on 10/6/2016
  • Figure: Targeting cysteines

    Seeking cysteines Targets & Mechanisms Targeting cysteines In a Science Signaling study published last month, researchers at The Scripps Research Institute identified two cysteines in PKCθ - Cys14 and Cys17 (yellow…

    Published on 10/6/2016
  • Table: BioCentury Product Profile

    Seeking cysteines Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Isoform-selective PKCθ inhibitor Concept A compound that suppresses T cell activation by …

    Published on 10/6/2016
  • Two-timing Ebola

    A bispecific antibody capable of neutralizing all Ebolavirus species

    The first compound to neutralize all five Ebolavirus species could provide an approach for tackling any virus with an intracellular target.

    Published on 9/29/2016
  • Hitting for the cycle

    Diversity-oriented chemistry expands the malaria drug universe

    Broad Institute scientists have identified an antimalarial compound with a new scaffold, against a new target, that hits all stages of the parasite's life cycle.

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Hitting for the cycle Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A single therapy for inhibiting all three stages of the parasite's life cycle, treating …

    Published on 9/29/2016
  • Figure: An inside job

    Two-timing Ebola Targets & Mechanisms An inside job This month in Science, a team led by researchers from the Albert Einstein College of Medicine described a "Trojan horse" bispecific antibody strategy with …

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Two-timing Ebola Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Bispecific antibody targeting all known species of Ebolavirus Concept Combines two mAbs …

    Published on 9/29/2016
  • Bon voyage!

    A Baylor team discovers how to culture norovirus, solving a 40-year-old problem

    Four decades after discovery of the norovirus, researchers have found a way to culture it in vitro that could boost chances of a vaccine.

    Published on 9/15/2016
  • Figure: Differential effect

    KOR-recting MS Targets & Mechanisms Differential effect Regrowing myelin sheaths that are lost from axons in patients with multiple sclerosis involves the proliferation of oligodendrocyte precursor cells (OPCs) in …

    Published on 9/15/2016
  • Table: BioCentury Product Profile

    KOR-recting MS Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A compound that activates kappa opioid receptor (KOR)-mediated differentiation of …

    Published on 9/15/2016
  • Table: Myelin modulators

    KOR-recting MS Targets & Mechanisms Myelin modulators Potential new remyelination modulators in multiple sclerosis. At least 15 targets are reported in the literature to regulate the development of oligodendrocytes…

    Published on 9/15/2016
  • Table: Pipeline in repair

    KOR-recting MS Targets & Mechanisms Pipeline in repair With myelin repair gaining momentum as a strategy to treat multiple sclerosis, at least 12 compounds or programs from 11 companies and 2 institutions, are now …

    Published on 9/15/2016
  • KOR-recting MS

    Why the MS field might invest in biased opioid agonists

    Two reports of successful myelin repair using kappa opioid agonists in models of MS add a known but tricky receptor to a growing list of remyelination targets.

    Published on 9/15/2016
  • Box: Bad guy's good side

    Biased against pain Targets & Mechanisms Bad guy's good side While the β-arrestin ARRB2 has been viewed as the bad actor in the side effects of opioid drugs, a Duke University Medical Center team has discovered the…

    Published on 9/1/2016
  • Figure: Breaking form

    Biased against pain Targets & Mechanisms Breaking form Creating safer opioid analgesics may require breaking away from the standard morphinan scaffold (red) found in classical opioids such as morphine, which bind …

    Published on 9/1/2016
  • Table: BioCentury Product Profile

    Biased against pain Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Biased agonist at the mu opioid receptor, MOR (PZM21 or derivative) Concept MOR binding …

    Published on 9/1/2016
  • Biased against pain

    How Epiodyne aims to make opioids safer

    Pushing the limits of computational drug discovery, an academic team finds a new type of molecule that separates good from bad signaling at opioid receptors.

    Published on 9/1/2016
  • Figure: Cleanup crew

    Forty Seven and counting Targets & Mechanisms Cleanup crew In a pair of Nature and Science Translational Medicine studies, Stanford University teams have shown blocking the "don't eat me" cell surface protein CD47 …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: Chasing CD47

    Forty Seven and counting Targets & Mechanisms Chasing CD47 At least six companies are developing compounds to block the anti-phagocytic cell surface protein CD47, either with CD47-targeting antibodies or with …

    Published on 8/25/2016
  • Forty Seven and counting

    Stanford and Forty Seven Inc. count up new indications for CD47 blockade

    With CD47 gaining status as the go-to target in oncology, a pair of Stanford studies suggest the target could extend to cardiovascular disease, transplant biology and more.

    Published on 8/25/2016
  • Box: A cut too far

    Niche for the aged Targets & Mechanisms A cut too far For effective wound repair, muscle stem cells - known as satellite cells - must spring into action and then return to quiescence. A study published last month …

    Published on 8/11/2016
  • Figure: Healing young again

    Niche for the aged Targets & Mechanisms Healing young again A pair of Nature Medicine studies have identified a receptor, integrin β1, and one of its ligands, fibronectin, which could be targeted to boost muscle …

    Published on 8/11/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993